Meta-analysis of genome-wide association data identifies four new susceptibility loci for colorectal cancer (original) (raw)

References

  1. Lichtenstein, P. et al. Environmental and heritable factors in the causation of cancer—analyses of cohorts of twins from Sweden, Denmark, and Finland. N. Engl. J. Med. 343, 78–85 (2000).
    Article CAS Google Scholar
  2. Aaltonen, L., Johns, L., Jarvinen, H., Mecklin, J.P. & Houlston, R. Explaining the familial colorectal cancer risk associated with mismatch repair (MMR)-deficient and MMR-stable tumors. Clin. Cancer Res. 13, 356–361 (2007).
    Article CAS Google Scholar
  3. Tomlinson, I. et al. A genome-wide association scan of tag SNPs identifies a susceptibility variant for colorectal cancer at 8q24.21. Nat. Genet. 39, 984–988 (2007).
    Article CAS Google Scholar
  4. Zanke, B.W. et al. Genome-wide association scan identifies a colorectal cancer susceptibility locus on chromosome 8q24. Nat. Genet. 39, 989–994 (2007).
    Article CAS Google Scholar
  5. Tomlinson, I.P. et al. A genome-wide association study identifies colorectal cancer susceptibility loci on chromosomes 10p14 and 8q23.3. Nat. Genet. 40, 623–630 (2008).
    Article CAS Google Scholar
  6. Tenesa, A. et al. Genome-wide association scan identifies a colorectal cancer susceptibility locus on 11q23 and replicates risk loci at 8q24 and 18q21. Nat. Genet. 40, 631–637 (2008).
    Article CAS Google Scholar
  7. Jaeger, E. et al. Common genetic variants at the CRAC1 (HMPS) locus on chromosome 15q13.3 influence colorectal cancer risk. Nat. Genet. 40, 26–28 (2008).
    Article CAS Google Scholar
  8. Broderick, P. et al. A genome-wide association study shows that common alleles of SMAD7 influence colorectal cancer risk. Nat. Genet. 39, 1315–1317 (2007).
    Article CAS Google Scholar
  9. Yeager, M. et al. Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat. Genet. 39, 645–649 (2007).
    Article CAS Google Scholar
  10. Kim, J.S. et al. Oncogenic β-catenin is required for bone morphogenetic protein 4 expression in human cancer cells. Cancer Res. 62, 2744–2748 (2002).
    CAS PubMed Google Scholar
  11. He, X.C. et al. BMP signaling inhibits intestinal stem cell self-renewal through suppression of Wnt-β-catenin signaling. Nat. Genet. 36, 1117–1121 (2004).
    Article CAS Google Scholar
  12. Howe, J.R. et al. Germline mutations of the gene encoding bone morphogenetic protein receptor 1A in juvenile polyposis. Nat. Genet. 28, 184–187 (2001).
    Article CAS Google Scholar
  13. Zhou, X.P. et al. Germline mutations in BMPR1A/ALK3 cause a subset of cases of juvenile polyposis syndrome and of Cowden and Bannayan-Riley-Ruvalcaba syndromes. Am. J. Hum. Genet. 69, 704–711 (2001).
    Article CAS Google Scholar
  14. Peck, J.W., Oberst, M., Bouker, K.B., Bowden, E. & Burbelo, P.D. The RhoA-binding protein, rhophilin-2, regulates actin cytoskeleton organization. J. Biol. Chem. 277, 43924–43932 (2002).
    Article CAS Google Scholar
  15. Bellovin, D.I. et al. Reciprocal regulation of RhoA and RhoC characterizes the EMT and identifies RhoC as a prognostic marker of colon carcinoma. Oncogene 25, 6959–6967 (2006).
    Article CAS Google Scholar
  16. Chang, Y.W., Marlin, J.W., Chance, T.W. & Jakobi, R. RhoA mediates cyclooxygenase-2 signaling to disrupt the formation of adherens junctions and increase cell motility. Cancer Res. 66, 11700–11708 (2006).
    Article CAS Google Scholar
  17. Behrens, J. The role of the Wnt signalling pathway in colorectal tumorigenesis. Biochem. Soc. Trans. 33, 672–675 (2005).
    Article CAS Google Scholar
  18. Wheeler, J.M. et al. Hypermethylation of the promoter region of the E-cadherin gene (CDH1) in sporadic and ulcerative colitis associated colorectal cancer. Gut 48, 367–371 (2001).
    Article CAS Google Scholar
  19. Guilford, P. et al. E-cadherin germline mutations in familial gastric cancer. Nature 392, 402–405 (1998).
    Article CAS Google Scholar
  20. Richards, F.M. et al. Germline E-cadherin gene (CDH1) mutations predispose to familial gastric cancer and colorectal cancer. Hum. Mol. Genet. 8, 607–610 (1999).
    Article CAS Google Scholar
  21. Salahshor, S. et al. A germline E-cadherin mutation in a family with gastric and colon cancer. Int. J. Mol. Med. 8, 439–443 (2001).
    CAS PubMed Google Scholar
  22. Li, L.C. et al. A single nucleotide polymorphism in the E-cadherin gene promoter alters transcriptional activities. Cancer Res. 60, 873–876 (2000).
    CAS PubMed Google Scholar
  23. Stranger, B.E. et al. Relative impact of nucleotide and copy number variation on gene expression phenotypes. Science 315, 848–853 (2007).
    Article CAS Google Scholar
  24. Stranger, B.E. et al. Genome-wide associations of gene expression variation in humans. PLoS Genet. 1, e78 (2005).
    Article Google Scholar
  25. Ghoussaini, M. et al. Multiple loci with different cancer specificities within the 8q24 gene desert. J. Natl. Cancer Inst. 100, 962–966 (2008).
    Article CAS Google Scholar
  26. Haiman, C.A. et al. A common genetic risk factor for colorectal and prostate cancer. Nat. Genet. 39, 954–956 (2007).
    Article CAS Google Scholar
  27. Penegar, S. et al. National study of colorectal cancer genetics. Br. J. Cancer 97, 1305–1309 (2007).
    Article CAS Google Scholar
  28. Eisen, T., Matakidou, A., Consortium, G. & Houlston, R. Identification of low penetrance alleles for lung cancer: The GEnetic Lung CAncer Predisposition Study (GELCAPS). BMC Cancer 8, 244 (2008).
    Article Google Scholar
  29. Smith, B.H. et al. Generation Scotland: the Scottish Family Health Study; a new resource for researching genes and heritability. BMC Med. Genet. 7, 74 (2006).
    Article Google Scholar
  30. Power, C. & Elliott, J. Cohort profile: 1958 British birth cohort (National Child Development Study). Int. J. Epidemiol. 35, 34–41 (2006).
    Article Google Scholar
  31. World Health Organization. International Classification of Diseases. 1975 Revision (World Health Organization, Geneva, 1977).
  32. Zhou, X.P. et al. Determination of the replication error phenotype in human tumors without the requirement for matching normal DNA by analysis of mononucleotide repeat microsatellites. Genes Chromosomes Cancer 21, 101–107 (1998).
    Article CAS Google Scholar
  33. Boland, C.R. et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res. 58, 5248–5257 (1998).
    CAS PubMed Google Scholar
  34. Petitti, D. Meta-analysis Decision Analysis and Cost-Effectiveness Analysis (Oxford, New York, Oxford, 1994).
    Google Scholar
  35. Higgins, J.P. & Thompson, S.G. Quantifying heterogeneity in a meta-analysis. Stat. Med. 21, 1539–1558 (2002).
    Article Google Scholar
  36. Houlston, R.S. & Ford, D. Genetics of coeliac disease. QJM 89, 737–743 (1996).
    Article CAS Google Scholar
  37. Cox, A. et al. A common coding variant in CASP8 is associated with breast cancer risk. Nat. Genet. 39, 352–358 (2007).
    Article CAS Google Scholar
  38. Johns, L.E. & Houlston, R.S. A systematic review and meta-analysis of familial colorectal cancer risk. Am. J. Gastroenterol. 96, 2992–3003 (2001).
    Article CAS Google Scholar
  39. Di Bernardo, M.C. et al. A genome-wide association study identifies six susceptibility loci for chronic lymphocytic leukemia. Nat. Genet. 40, 1204–1210 (2008).
    Article CAS Google Scholar
  40. Skol, A.D., Scott, L.J., Abecasis, G.R. & Boehnke, M. Joint analysis is more efficient than replication-based analysis for two-stage genome-wide association studies. Nat. Genet. 38, 209–213 (2006).
    Article CAS Google Scholar
  41. Antoniou, A.C. & Easton, D.F. Polygenic inheritance of breast cancer: Implications for design of association studies. Genet. Epidemiol. 25, 190–202 (2003).
    Article Google Scholar
  42. Garcia-Closas, M. & Lubin, J.H. Power and sample size calculations in case-control studies of gene-environment interactions: comments on different approaches. Am. J. Epidemiol. 149, 689–692 (1999).
    Article CAS Google Scholar
  43. Lubin, J.H. & Gail, M.H. On power and sample size for studying features of the relative odds of disease. Am. J. Epidemiol. 131, 552–566 (1990).
    Article CAS Google Scholar
  44. Cuzick, J. A Wilcoxon-type test for trend. Stat. Med. 4, 87–90 (1985).
    Article CAS Google Scholar

Download references

Acknowledgements

Cancer Research UK provided principal funding for this study (A6360). We would like to thank all individuals that participated in this study.

Institute of Cancer Research: Work was supported by the Bobby Moore Cancer Research UK (C1298/A8362). Additional funding was provided by the European Union (CPRB LSHC-CT-2004-503465) and CORE. I.C. was in receipt of a clinical training fellowship from St George's Hospital Medical School. S.L. was supported by a PhD studentship from Cancer Research UK. We are grateful to colleagues at the UK National Cancer Research Network.

Oxford: Work was supported by CORE and the Bobby Moore Fund. We are grateful to colleagues at UK Clinical Genetics Centres and the UK National Cancer Research Network.

Edinburgh: The work was supported by Cancer Research UK grant numbers C348/A3758 and A8896, C48/A6361 and the Bobby Moore Fund, which supports the work of the Colon Cancer Genetics Group through Cancer Research UK. Additional funding was provided by the Medical Research Council (G0000657-53203), Scottish Executive Chief Scientist's Office (K/OPR/2/2/D333, CZB/4/449), center grant from CORE as part of the Digestive Cancer Campaign. J.P. was funded by an MRC PhD studentship. We gratefully acknowledge the work of the COGS and SOCCS administrative teams; R. Cetnarskyj and the research nurse teams, all who recruited to the studies; the Wellcome Trust Clinical Research Facility for sample preparation; and all clinicians and pathologists throughout Scotland at collaborating centers. The study used the biological and data resource of Generation Scotland.

Finland: This work was supported by grants from Academy of Finland (Finnish Centre of Excellence Program 2006-2011), the Finnish Cancer Society, the Sigrid Juselius Foundation and the European Commission (9LSHG-CT-2004-512142).

Cambridge: We thank the SEARCH study team and all the participants in the study. P.D.P.P. is a Cancer Research UK Senior Clinical Research Fellow. T.K. is funded by the Foundation Dr Henri Dubois-Ferriere Dinu Lipatti.

Kiel: The study was supported by the German National Genome Research Network (NGFN) through the PopGen biobank (BmBF 01GR0468) and the National Genotyping Platform. Further support was obtained through the MediGrid and Services@MediGrid projects (01AK803G and 01IG07015B). SHIP is part of the Community Medicine Research net (CMR) of the University of Greifswald, Germany, which is funded by the Federal Ministry of Education and Research (grant number. ZZ9603), the Ministry of Cultural Affairs as well as the Social Ministry of the Federal State of Mecklenburg-West Pomerania.

Heidelberg: We wish to thank all participants and the staff of the participating clinics for their contribution to the data collection, B. Kaspereit, K. Smit and U. Eilber in the Division of Cancer Epidemiology, and U. Handte-Daub, S. Toth and B. Collins in the Division of Clinical Epidemiology and Aging Research, German Cancer Research Center for their excellent technical assistance. This study was supported by the German Research Council (Deutsche Forschungsgemeinschaft), grant numbers BR 1704/6-1, BR 1704/6-3 and CH 117/1-1, and by the German Federal Ministry for Education and Research, grant number 01 KH 0404.

Canada: We gratefully acknowledge the contribution of A. Belisle, V. Catudal and R. Fréchette. Cancer Care Ontario, as the host organization to the ARCTIC Genome Project, acknowledges that this project was funded by Genome Canada through the Ontario Genomics Institute, by Génome Québec, the Ministère du Dévelopement Économique et Régional et de la Recherche du Québec and the Ontario Institute for Cancer Research (B.W.Z., T.J.H. and S.G.). Additional funding was provided by the National Cancer Institute of Canada (NCIC) through the Cancer Risk Assessment (CaRE) Program Project Grant. The work was supported through collaboration and cooperative agreements with the Colon Cancer Family Registry and PIs, supported by the National Cancer Institute, National Institutes of Health under RFA CA-95-011, including the Ontario Registry for Studies of Familial Colorectal Cancer (S.G.) (U01 CA076783). The content of this manuscript does not necessarily reflect the views or policies of the National Cancer Institute or any of the collaborating institutions or investigators in the Colon CFR, nor does mention of trade names, commercial products or organizations imply endorsement by the US Government or the Colon CFR.

This study made use of genotyping data on the 1958 Birth Cohort. Genotyping data on controls was generated and generously supplied to us by Panagiotis Deloukas of the Wellcome Trust Sanger Institute. A full list of the investigators who contributed to the generation of the data is available from http://www.wtccc.org.uk.

Author information

Authors and Affiliations

  1. Section of Cancer Genetics, Institute of Cancer Research, SM2 5NG, Sutton, UK
    Richard S Houlston, Emily Webb, Peter Broderick, Alan M Pittman, Maria Chiara Di Bernardo, Steven Lubbe, Ian Chandler, Jayaram Vijayakrishnan, Kate Sullivan & Steven Penegar
  2. Molecular and Population Genetics, Wellcome Trust Centre for Human Genetics, Roosevelt Drive, OX3 7BN, Oxford, UK
    Luis Carvajal-Carmona, Kimberley Howarth, Emma Jaeger, Sarah L Spain, Axel Walther, Ella Barclay, Lynn Martin, Maggie Gorman, Enric Domingo, Ana S Teixeira & Ian P M Tomlinson
  3. Department of Clinical Pharmacology, Oxford University, Old Road Campus Research Building, OX2 6HA, Oxford, UK
    David Kerr
  4. Bioinformatics and Biostatistics, Wellcome Trust Centre for Human Genetics, Roosevelt Drive, OX3 7BN, Oxford, UK
    Jean-Baptiste Cazier
  5. Department of Medical Genetics, Genome-Scale Biology Research Program, Biomedicum Helsinki, University of Helsinki, Helsinki, Finland
    Iina Niittymäki, Sari Tuupanen, Auli Karhu & Lauri A Aaltonen
  6. Colon Cancer Genetics Group, Institute of Genetics and Molecular Medicine, University of Edinburgh and MRC Human Genetics Unit, Edinburgh, EH4 2XU, UK
    Susan M Farrington, Albert Tenesa, James G D Prendergast, Rebecca A Barnetson, Harry Campbell & Malcolm G Dunlop
  7. Clinical Genetics, Western General Hospital, EH4 2XU, Edinburgh, UK
    Roseanne Cetnarskyj & Mary E Porteous
  8. Strangeways Research Laboratory Department of Oncology, Cancer Research UK Laboratories, University of Cambridge, Cambridge, UK
    Paul D P Pharoah & Thibaud Koessler
  9. Department of General Internal Medicine, University Hospital, Schleswig-Holstein, Campus Kiel, Schittenhelmstraße 12, 24105, Kiel, Germany
    Jochen Hampe & Stephan Buch
  10. POPGEN Biobank, University Hospital Schleswig-Holstein, Campus Kiel, Schittenhelmstrasse 12, 24105, Kiel, Germany
    Clemens Schafmayer & Stefan Schreiber
  11. Department of General and Thoracic Surgery, University Hospital Schleswig-Holstein, Campus Kiel, Arnold-Heller-Strasse, 24105, Kiel, Germany
    Clemens Schafmayer & Jurgen Tepel
  12. Institute for Clinical Molecular Biology, University Hospital Schleswig-Holstein, Campus Kiel, Schittenhelmstrasse 12, 24105, Kiel, Germany
    Stefan Schreiber
  13. Institut für Epidemiologie und Sozialmedizin, University Hospital Greifswald, Walther-Rathenau-Strasse 48, Greifswald, 17487, Germany
    Henry Völzke
  14. Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120, Heidelberg, Germany
    Jenny Chang-Claude
  15. Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, Heidelberg, 69120, Germany
    Michael Hoffmeister & Hermann Brenner
  16. Division of Epidemiology, The Ottawa Health Research Institute, 501 Smythe Road, Ottawa, K1H 8L6, Canada
    Brent W Zanke
  17. The McGill University and Genome Quebec Innovation Centre, 740 Dr Penfield Avenue, Montreal, H3G 1A4, Quebec, Canada
    Alexandre Montpetit & Thomas J Hudson
  18. Cancer Care Ontario, 620 University Avenue, Toronto Ontario M5G 1L7 and Ontario Institute for Cancer Research, 101 College Street, Toronto, M5G 2L7, Canada
    Thomas J Hudson & Steven Gallinger

Consortia

COGENT Study

Contributions

The study was designed and financial support obtained by R.S.H., I.P.M.T., M.G.D. and H.C. The manuscript was drafted by R.S.H. and E.W. with contributions from M.G.D. and I.P.M.T. Statistical analyses were conducted by E.W., with contributions from M.C.D.B., J.-B.C., S.L.S. and A.T. E.W. and A.M.P. performed bioinformatic analyses.

Institute of Cancer Research: Subject recruitment and sample acquisition to NSCCG were undertaken by S.P. Coordination of sample preparation and genotyping was performed by P.B. Sample preparation and genotyping performed by A.M.P., K.S., J.V. and S.L. Histology review was by I.C. Testing of MSI was performed by S.L. and I.C.

Wellcome Trust Centre for Human Genetics: Subject recruitment and sample acquisition were undertaken by E.B., M.G., L.M. and members of the CoRGI Consortium and D.K. Sample preparation was performed by K.H., S.L.S. and E.J. Genotyping was performed and co-ordinated by L.C.-C., K.H., A.S.T., S.L.S., A.W., E.J. and E.D.

Colon Cancer Genetics Group, Edinburgh: Study design and funding: M.G.D., H.C., A.T., S.M.F. and M.E.P. Subject recruitment and sample acquisition was led by M.G.D., H.C., M.E.P., R.C., S.M.F. and members of the SOCCS/COGS study teams. Sample preparation was co-ordinated by S.M.F. and R.A.B. Histology review: M.G.D. and S.M.F. Genotyping was performed and co-ordinated by S.M.F. and M.G.D. A.T. performed statistical analyses. J.G.P. performed bioinformatic analyses. The following authors from the various collaborating groups conceived the local study, undertook assembly of case/control series in their respective regions, collected data and samples, variously undertook genotyping and analysis: I.N., S.T., A.K. and L.A.A. in Finland; T.K. and P.D.P. in Cambridge; S.S., H.V., S.B., C.S., J.T. and J.H. in Kiel; J.C.-C., M.H. and H.B. in Heidelberg; B.W.Z., A.M., T.J.H. and S.G., in Toronto and Montreal. All undertook sample collection and phenotype data collection and collation in the respective centers.

Corresponding authors

Correspondence toRichard S Houlston, Ian P M Tomlinson or Malcolm G Dunlop.

Additional information

A full list of authors and affiliations is provided at the end of this paper.

A full list of members is provided in the Supplementary Note.

A full list of members is provided in the Supplementary Note.

A full list of members is provided in the Supplementary Note.

Supplementary information

Rights and permissions

About this article

Cite this article

COGENT Study. Meta-analysis of genome-wide association data identifies four new susceptibility loci for colorectal cancer.Nat Genet 40, 1426–1435 (2008). https://doi.org/10.1038/ng.262

Download citation